Core Insights - Three companies, Zhiyu, Tianshu Zhixin, and Jingfeng Medical-B, successfully listed on the Hong Kong Stock Exchange on January 8, 2026, with first-day gains of 13.17%, 8.44%, and 30.90% respectively [1][4]. Company Summaries - **Zhiyu**: As the world's first publicly listed company focused on a general artificial intelligence (AGI) foundational model, Zhiyu has gained significant attention from investors. The company, founded in 2019, has developed a 100 billion parameter model (GLM-130B) and supports over 8,000 institutional clients and approximately 80 million devices. It holds a 6.6% market share among independent general model developers in China, ranking first in the country and second globally based on projected 2024 revenue [5][6]. - **Tianshu Zhixin**: This company specializes in providing general GPU products and AI computing solutions across various industries. Its product lineup includes general GPU chips and customized AI computing solutions, with over 52,000 GPU products delivered to more than 290 clients across sectors such as finance, healthcare, and transportation. Tianshu Zhixin has achieved over 900 deployments and applications in critical fields, supporting industrial digital transformation [6][7]. - **Jingfeng Medical-B**: Established in 2017, Jingfeng Medical-B is a leading company in the surgical robotics sector. It is the first in China and the second globally to receive regulatory approval for multiple types of surgical robots. The company's core product, the Jingfeng multi-port laparoscopic surgical robot, received approval in December 2022 and has expanded its clinical applications. In 2024, it sold 20 units, ranking first among domestic surgical robot manufacturers [7][8]. Market Reception - All three companies experienced strong demand during their public offerings, with Zhiyu and Jingfeng Medical-B achieving over 1,000 times oversubscription in the public offering phase, while Tianshu Zhixin had an oversubscription of 414.24 times [8][9]. - The strong performance of these IPOs has contributed to a positive sentiment in the Hong Kong IPO market, with expectations that upcoming listings may also perform well [4][11]. Institutional Interest - The three companies attracted significant interest from institutional investors, with Zhiyu securing a diverse base of cornerstone investors, including major public funds and private equity firms, totaling HKD 2.98 billion in subscriptions [9][10]. - Tianshu Zhixin and Jingfeng Medical-B also have backing from prominent institutions such as UBS and the Abu Dhabi Investment Authority, indicating strong confidence in their business models and growth potential [10]. Upcoming Listings - The Hong Kong market is witnessing a surge in new listings, with additional companies set to debut shortly after the successful IPOs of Zhiyu, Tianshu Zhixin, and Jingfeng Medical-B [11][12].

证券日报网讯1月8日，力合科创（002243）在互动平台回答投资者提问时表示，微灵医疗是公司的参股 企业，主要从事医疗级全植入式无线脑机接口系统研发；公司未投资脑虎科技。 ...

Core Viewpoint - The company Fuhua (301371) is progressing in its R&D projects, with specific timelines and developments for its medical devices and injectable products outlined for 2025 [1] R&D Progress - The company has a Class III medical device, "Recombinant Type III Humanized Collagen Dressing," which has entered the clinical stage for 2025 [1] - For injectable products, the clinical trials for the "Recombinant Type III Humanized Collagen Lyophilized Fiber" project have been completed, and the company is preparing the clinical trial summary report [1] - The "Recombinant Type III Humanized Collagen Gel" project is still in the R&D phase, with plans to initiate clinical trials this year [1] - Further updates on other R&D projects will be available in the annual report scheduled for release in April [1]

Core Viewpoint - The company, Huayang Intelligent, aims to achieve growth through a dual-driven strategy and diversified performance growth points, focusing on precision motors and medical devices as key areas for development [1] Group 1: Strategic Goals - The overall operational goal is to strengthen the precision motor segment and become an industry leader in medical devices [1] - The strategic direction emphasizes deep layout and collaborative development in the micro-special motor and healthcare sectors [1] Group 2: Development Strategy - The company plans to consolidate its existing core business and enhance the market competitiveness of its micro-special motors and components [1] - There is a commitment to driving business development through technological innovation, particularly in the precision drug delivery device sector [1] - The company aims to expand the application of motor products into emerging areas such as smart home, automotive, and robotics, establishing a diversified strategic blueprint centered on micro-special motors and healthcare [1]

Core Viewpoint - The article discusses the recent IPOs of three companies—Zhiyu, Tianshu Zhixin, and Jingfeng Medical-B—on the Hong Kong Stock Exchange, highlighting their strong market performance and investor interest in the context of a rising trend in IPOs for 2026 [1][5][13]. Group 1: Company Performance - Zhiyu, Tianshu Zhixin, and Jingfeng Medical-B saw first-day gains of 13.17%, 8.44%, and 30.90% respectively, indicating strong market reception [2][4]. - All three companies entered the market with significant oversubscription rates, with Zhiyu and Jingfeng Medical-B exceeding 1,000 times in public offerings, while Tianshu Zhixin had a subscription rate of 414.24 times [7][11]. Group 2: Company Profiles - Zhiyu is recognized as the world's first publicly listed company focused on general artificial intelligence (AGI) foundational models, having developed a 100 billion parameter model and serving over 8,000 institutional clients [7][8]. - Tianshu Zhixin specializes in general GPU products and AI computing solutions, delivering over 52,000 GPU products to more than 290 clients across various industries [8]. - Jingfeng Medical-B is a leading surgical robotics company in China, having received regulatory approval for multiple robotic systems and achieving significant sales in the domestic market [9][10]. Group 3: Market Trends - The article notes a resurgence in IPO activity in Hong Kong, with several companies scheduled to list in early 2026, indicating a potential bullish trend for the market [14][21]. - The strong performance of newly listed companies may rekindle investor enthusiasm for IPOs, as seen with the recent gains in dark trading for companies like MINIMAX-WP and others [16][20].

亚辉龙透露，公司与脑机星链拟合作研发的相关领域均为非侵入式技术路径，目前尚处于早期阶段，相 关项目预估研发投入3000万元左右，公司具体投入金额尚需根据研发项目实际情况，结合公司自身需求 以及未来与脑机星链的协商最终确定。相关项目开发周期较长，存在不确定性，双方也尚未明确合作的 具体安排。 亚辉龙还特别强调，公司拟投资脑机星链的金额为不超过1500万元，投资金额占公司货币资金的比例较 低，不会对公司正常经营造成重大影响，同时相关研发及业务合作目前尚处于早期阶段，中短期内不会 给公司带来明显业绩改善或构成重大影响，从长期来看该合作有利于完善公司业务布局。公司及有关责 任人被予以监管警示 每经记者｜甄素静 每经编辑｜陈旭 1月8日，亚辉龙（SH688575，股价15.81元，总市值90.34亿元）发布关于上交所问询函的回复公告，围 绕公司与深圳脑机星链科技有限公司（以下简称脑机星链）签订《战略合作框架协议》的相关问询作出 回应。 公告从技术路线、研发进展、资金投入到产业协同逻辑等方面进行了披露，明确上述合作项目预估研发 投入约3000万元，公司根据脑机星链的具体融资计划及估值综合考虑，对脑机星链的投资规模将不超过 ...

Core Viewpoint - Shenzhen Precision Medical Technology Co., Ltd. (referred to as Precision Medical) successfully listed on the Hong Kong Stock Exchange on January 8, with an opening increase of 36.45%, reaching HKD 59.00 per share, and a market capitalization of HKD 22.876 billion [1][4]. Company Overview - Precision Medical's IPO was priced at HKD 43.24 per share, with a total issuance of 27.7222 million shares, raising a net amount of HKD 1.117 billion [4]. - The company has received approval for three surgical robot products, including the MP1000 and SP1000, which are already in clinical use across various surgical fields [5][6]. Investment and Market Position - The investor lineup for Precision Medical includes prominent firms such as Sequoia China, Temasek, and UBS AM Singapore, with total subscriptions amounting to USD 75 million [5]. - The company has completed over 12,000 robot-assisted surgeries using the MP1000 and over 2,000 using the SP1000 prior to the IPO [8]. Industry Context - The surgical robot market in China is projected to grow from RMB 2.714 billion in 2019 to RMB 7.184 billion by 2024, with a compound annual growth rate (CAGR) of 21.5% [11]. - The market is competitive, with major players like Intuitive Surgical's da Vinci system holding over 60% of the high-end market share, while domestic companies like MicroPort and Tianzhihang are also emerging [11]. Financial Performance - Precision Medical reported revenues of RMB 48.042 million, RMB 160 million, and RMB 149 million for 2023, 2024, and the first half of 2025, respectively, with corresponding losses of RMB 213 million, RMB 219 million, and RMB 89.087 million [12]. - The company has maintained high R&D expenditures, amounting to RMB 171 million, RMB 226 million, and RMB 97 million during the same periods, which supports product innovation but increases short-term profitability pressure [12].

证券之星消息，截至2026年1月8日收盘，开立医疗(300633)报收于28.85元，上涨0.59%，换手率 1.42%，成交量6.14万手，成交额1.77亿元。 1月8日的资金流向数据方面，主力资金净流出1523.37万元，占总成交额8.59%，游资资金净流入 2890.71万元，占总成交额16.29%，散户资金净流出1367.34万元，占总成交额7.71%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有10家机构 ...

2025年，A股总市值站上100万亿元的高峰，上证指数涨破4000点创下近十年新高。2026年A股市场又将 如何演绎？哪些行业将孕育新的投资机遇？ 搜狐财经《基金佳问》栏目特别推出"基遇2026"专题系列报道，复盘A股市场细分领域年内行情，展望 及预测2026年各热门赛道的投资机遇，把握后市资产配置的主逻辑，寻找具有投资潜力的基金产品。 1月7日，创金合信全球医药生物（QDII）基金经理毛丁丁做客搜狐财经直播间，回顾了过去一年A股医 药板块的结构性行情，并对2026年医药板块走势、投资脉络进行了深度解析。 "2025年医药板块整体回暖，但结构性差异巨大。"毛丁丁分析指出，申万生物医药指数去年涨了约十个 点，但仍跑输沪深300。创新药板块成为最大亮点，而医疗器械、医疗服务等其他领域表现平平。 创新药板块的强势表现并非贯穿全年。毛丁丁指出，创新药主要在2025年3月至7月期间上涨，随后从9 月开始持续回调至年底。这一调整主要由于二三季度上涨过快、涨幅过大所致。 他分析道，恒生医疗保健、申万化学制药等代表性指数在去年8、9月份时，估值已超过历史估值中枢一 倍标准差水平，需要时间消化前期涨幅。 对于A股、港股、美股市 ...

证券日报网讯 1月8日，戴维医疗发布公告称，宁波戴维医疗器械股份有限公司（以下简称"公司"）全 资孙公司宁波甬星医疗仪器有限公司于近日取得由浙江省药品监督管理局颁发的1项《医疗器械生产许 可证》（许可证编号：浙药监械生产许20110078号），本次主要涉及医疗器械生产许可证延续事项已通 过审批。 （编辑 楚丽君） ...